This includes activating the expression of genes known to induce malignancy (ATAD2 (ATPase family AAA domain containing 2) [122]) and genes that have been implicated in reduced survival in lung adenocarcinoma patients (GBE1 (glycogen branching enzyme), HK2 (hexokinase 2) [125]). This evidence concerns the gene GBE1 and lung adenocarcinoma.